Poly-N-acetyl glucosamine (PNAG/dPNAG)-binding peptides and methods of use thereof
US7786255B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 21, 2005 |
| Grant date | Aug 31, 2010 |
| Priority date | — |
| Expiry date | Dec 10, 2026 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.